Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
h5nudVC9gMc9tQw8